Study Details
Description:
This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 in participants with neurotensin receptor 1 (NTSR1)-expressing solid tumours.
Sponsor:
Fusion Pharmaceuticals, Inc.Contacts:
Clinical Trialsclinicaltrials@fusionpharma.com
1 (888) 506-4215
Government Study Link:
NCT05605522 - Click here to see study onClinicalTrials.gov
Inclusion
- Histologically or cytologically confirmed solid tumor prostrate metastatically/locally advamced PDAC CRC,NED
- disease that has progressed despite prior treatment and for which additional effective standard therapy is not available
- sufficient target expression at least 1 measurable lesion finding by Imaging following injection of In-FPI-2058
- Measurable disease per RECIST v1.1
- Tumor tissue(either archival within last 24 month or fresh biopsy
Exclusion
Exclusion Criteria Not Yet Provided
Patient Education
Patient Education Not Yet Provided
Publications
Locations
United States